8-K - AbbVie Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

AbbVie discloses $744 million Q1 2026 acquired IPR&D and milestones expense, reducing both GAAP and adjusted diluted EPS by $0.41, with updated full-year 2026 adjusted EPS guidance of $13.96-$14.16.

Key Takeaways

1Q1 2026 acquired IPR&D and milestones expense of $744 million pre-tax impacts both GAAP and adjusted diluted EPS by $(0.41).

2Q1 2026 adjusted diluted EPS guidance range is $2.56-$2.60 including the expense.

3Full-year 2026 adjusted diluted EPS guidance updated to $13.96-$14.16 incorporating Q1 expense.

4Previous full-year guidance excluding Q1 expense was $14.37-$14.57.

5Guidance excludes future IPR&D and milestones expenses beyond Q1 due to uncertainty.

6Q1 2026 results not finalized and subject to financial closing procedures.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2026 are expected to include acquir

Financial Results

$744.0M$13.96$14.16$2.56

9.01

Financial Statements and Exhibits (d) Exhibits Exhibit No.: 99.1 | Exhibit: Guidance including the impact of acquired IPR&D and milestones expense . Exhibit No.

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1